Subscribe
pabradyphoto-2-
pabradyphoto / iStockphoto.com
31 August 2017Americas

FTC orders Baxter to divest rights in Claris deal

The Federal Trade Commission (FTC) has approved a final order combating the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’s injectable drugs business.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
Federal Circuit affirms PTAB’s Baxter ruling
11 March 2021   The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents.
Americas
Baxter sues B.Braun in revived kidney treatment patent dispute
16 November 2020   American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.


Editor's picks

Explainer: ARIPO’s role in Plant Variety Protection
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025

Editor's picks

Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025

More on this story

Medtech
Federal Circuit affirms PTAB’s Baxter ruling
11 March 2021   The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents.
Americas
Baxter sues B.Braun in revived kidney treatment patent dispute
16 November 2020   American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

More on this story

Medtech
Federal Circuit affirms PTAB’s Baxter ruling
11 March 2021   The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents.
Americas
Baxter sues B.Braun in revived kidney treatment patent dispute
16 November 2020   American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Explainer: ARIPO’s role in Plant Variety Protection
J&J sues over schizophrenia drug generic following patent victory
WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids